Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Earnings for Repare Therapeutics Inc. (RPTX)
Earnings in 2023 (TTM): $-103,179,000
According to Repare Therapeutics Inc.'s latest financial reports the company's current earnings (TTM) are $-103,179,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Repare Therapeutics Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-103,179,000 | $-93,796,000 |
| 2022 | $-13,900,000 | $-29,047,000 |
| 2021 | $-108,586,000 | $-106,908,000 |
| 2020 | $-54,742,000 | $-53,417,000 |
| 2019 | $-27,021,000 | $-27,216,000 |
| 2018 | $-14,248,000 | $-14,283,000 |
| 2017 | $-7,796,000 | $-7,796,000 |